多替阿巴拉米片治疗艾滋病的效果如何？

How effective is the treatment for AIDS? Dolutegravir tablets are China's first complete single-tablet three-in-one preparation with DTG (dolutegravir) as the core. Today we will learn more about its effectiveness in treating AIDS from some trials.

In SINGLE, 833 patients received dolutegravir 50 mg once daily plus fixed-dose abacavir-lamivudine (DTG-ABC/3TC) or fixed-dose efavirenz-tenofodoxine-emtricitabine (EFV/TDF/FTC). In the 48-week primary analysis, the proportion of patients achieving virological suppression was better in the dolutegravir XxXABC/3TC group than in the FTC/TDF/ETC group, p=0.003. The same treatment difference was observed among subjects defined by baseline HIV RNA levels (or 100,000 copies/ml). Patients could maintain virological suppression during the 1440 weeks of the SINGLE open period, and the DTGXxXABC/3TC group (71%) was better than the EFV/TDF/FTC group (63%), with a treatment difference of 8.3% (2.0, 14.6).

In FLANINGO, 485 patients received dolutegravir 50 mg once daily or darunavir/ritonavir (DRX/rD 800 mg/100 mg once daily), all in combination with ABC/3TC (approximately 33%) or TDF/FTC (approximately 67%). All treatments were administered in an open-label manner. At week 96, dolutegravir virologic suppression in the DRY/r group (80%) versus the DRY/r group (68%) Adjusted treatment difference [DTG-(DRVXxXRTV)]: 12.4%; 95% CI: [4.7, 20.2]) 2 Response rates at Week 96 were 82% (DTGXxXABC/3TC) and 75% (DRV/rXxXABC/3TC).

In summary, the virological suppression rate is significantly higher than that of other experimental groups, and it is a good choice for the treatment of AIDS.